Results 31 to 40 of about 22,351 (243)
Multiple Sclerosis and Related Disorders, 2023 BACKGROUND Cladribine tablets and fingolimod have similar marketing authorisations in Europe for the treatment of patients with highly active relapsing multiple sclerosis (HA-RMS).
W. Brownlee +8 more
semanticscholar +1 more source
Preclinical characterisation of fingolimod as a potential therapeutic agent for stroke [PDF]
, 2022 Stroke is the leading cause for death and disability worldwide, and the search for novel drug treatments has been affected by repeated clinical trial failures.
Diaz Diaz, Andrea C.
core
Biernacki-et-al.Real-world-data-on-the-efficacy-and-long-term-use-of-fingolimod-in-Hungary.xlsx
, 2022 Background: Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012.
Biernacki Tamás (12190799)
core +1 more source
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod
Frontiers in Pharmacology, 2022 Fingolimod is a well-tolerated, highly effective disease-modifying therapy successfully utilized in the management of multiple sclerosis. The active metabolite, fingolimod-phosphate, acts on sphingosine-1-phosphate receptors (S1PRs) to bring about an ...
Safura Pournajaf +3 more
semanticscholar +1 more source
Journal of Neurology Neurosurgery & Psychiatry, 2022 Background SARS-CoV-2 mRNA vaccination of healthy individuals is highly immunogenic and protective against severe COVID-19. However, there are limited data on how disease-modifying therapies (DMTs) alter SARS-CoV-2 mRNA vaccine immunogenicity in patients
L. Meyer-Arndt +24 more
semanticscholar +1 more source
BMC Neurology, 2017 Background Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse.
Anat Achiron +7 more
doaj +1 more source
Frontiers in Bioengineering and Biotechnology, 2020 Researchers are investigating the use of biomaterials with aligned guidance cues, like those provided by aligned electrospun fibers, to facilitate axonal growth across critical-length peripheral nerve defects. To enhance the regenerative outcomes further,
Devan L. Puhl +18 more
doaj +1 more source
Molecular Neurobiology, 2022 Therapeutic strategies for Alzheimer’s disease (AD) have largely focused on the regulation of amyloid pathology while those targeting tau pathology, and inflammatory mechanisms are less explored.
S. Fagan, Sibylle Béchet, K. Dev
semanticscholar +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018 Background Fingolimod is approved for the treatment of highly active relapsing–remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK.
Gordon Mazibrada +2 more
doaj +1 more source
Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin [PDF]
BioImpacts, 2023 Introduction: Fingolimod is a drug that is used to treat multiple sclerosis (MS). It has pH-dependent solubility and low solubility when buffering agents are present.
Samira Gholizadeh +5 more
doaj +1 more source